1
|
Leduc S, De Schepper M, Richard F, Maetens M, Pabba A, Borremans K, Jaekers J, Latacz E, Zels G, Bohlok A, Van Baelen K, Nguyen HL, Geukens T, Dirix L, Larsimont D, Vankerckhove S, Santos E, Oliveira RC, Dede K, Kulka J, Borbala S, Salamon F, Madaras L, Marcell Szasz A, Lucidi V, Meyer Y, Topal B, Verhoef C, Engstrand J, Moro CF, Gerling M, Bachir I, Biganzoli E, Donckier V, Floris G, Vermeulen P, Desmedt C. Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases. NPJ Breast Cancer 2023; 9:100. [PMID: 38102162 PMCID: PMC10724185 DOI: 10.1038/s41523-023-00602-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2023] [Accepted: 11/13/2023] [Indexed: 12/17/2023] Open
Abstract
Liver is the third most common organ for breast cancer (BC) metastasis. Two main histopathological growth patterns (HGP) exist in liver metastases (LM): desmoplastic and replacement. Although a reduced immunotherapy efficacy is reported in patients with LM, tumor-infiltrating lymphocytes (TIL) have not yet been investigated in BCLM. Here, we evaluate the distribution of the HGP and TIL in BCLM, and their association with clinicopathological variables and survival. We collect samples from surgically resected BCLM (n = 133 patients, 568 H&E sections) and post-mortem derived BCLM (n = 23 patients, 97 H&E sections). HGP is assessed as the proportion of tumor liver interface and categorized as pure-replacement ('pure r-HGP') or any-desmoplastic ('any d-HGP'). We score the TIL according to LM-specific guidelines. Associations with progression-free (PFS) and overall survival (OS) are assessed using Cox regressions. We observe a higher prevalence of 'any d-HGP' (56%) in the surgical samples and a higher prevalence of 'pure r-HGP' (83%) in the post-mortem samples. In the surgical cohort, no evidence of the association between HGP and clinicopathological characteristics is observed except with the laterality of the primary tumor (p value = 0.049) and the systemic preoperative treatment before liver surgery (p value = .039). TIL is less prevalent in 'pure r-HGP' as compared to 'any d-HGP' (p value = 0.001). 'Pure r-HGP' predicts worse PFS (HR: 2.65; CI: (1.45-4.82); p value = 0.001) and OS (HR: 3.10; CI: (1.29-7.46); p value = 0.011) in the multivariable analyses. To conclude, we demonstrate that BCLM with a 'pure r-HGP' is associated with less TIL and with the worse outcome when compared with BCLM with 'any d-HGP'. These findings suggest that HGP could be considered to refine treatment approaches.
Collapse
Affiliation(s)
- Sophia Leduc
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
| | - Maxim De Schepper
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
- Department of Pathology, University Hospitals Leuven, Leuven, Belgium
| | - François Richard
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
| | - Marion Maetens
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
| | - Anirudh Pabba
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
| | - Kristien Borremans
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
- Department of Gynecological Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Joris Jaekers
- Department of Abdominal Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Emily Latacz
- Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium
| | - Gitte Zels
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
- Department of Pathology, University Hospitals Leuven, Leuven, Belgium
| | - Ali Bohlok
- Department of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Karen Van Baelen
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
- Department of Gynecological Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Ha Linh Nguyen
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
| | - Tatjana Geukens
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium
| | - Luc Dirix
- Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium
| | - Denis Larsimont
- Department of Anatomopathology, Institut Jules Bordet, Brussels, Belgium
| | - Sophie Vankerckhove
- Department of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Eva Santos
- General Surgery Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal
| | - Rui Caetano Oliveira
- General Surgery Department, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal
| | - Kristòf Dede
- Department of Surgical Oncology, Uzsoki Hospital, Budapest, Hungary
| | - Janina Kulka
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary
| | - Székely Borbala
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary
| | - Ferenc Salamon
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary
| | - Lilla Madaras
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary
- Department of Pathology, Uzsoki Hospital, Budapest, Hungary
| | - A Marcell Szasz
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary
| | - Valerio Lucidi
- Department of Abdominal Surgery, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium
| | - Yannick Meyer
- Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Baki Topal
- Department of Abdominal Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Cornelis Verhoef
- Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
| | - Jennie Engstrand
- Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
| | - Carlos Fernandez Moro
- Department of Biosciences and Nutrition, Karolinska Institute, Huddinge and Karolinska University Hospital, Solna, Sweden
| | - Marco Gerling
- Department of Biosciences and Nutrition, Karolinska Institute, Huddinge and Karolinska University Hospital, Solna, Sweden
| | - Imane Bachir
- Department of Anesthesiology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Elia Biganzoli
- Unit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) "L. Sacco" & DSRC, LITA Vialba campus, University of Milan, Milan, Italy
| | - Vincent Donckier
- Department of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - Giuseppe Floris
- Department of Pathology, University Hospitals Leuven, Leuven, Belgium
- Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Peter Vermeulen
- Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium
| | - Christine Desmedt
- Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium.
| |
Collapse
|
2
|
Barna AJ, Herold Z, Acs M, Bazsa S, Gajdacsi J, Garay TM, Herold M, Madaras L, Muhl D, Nagy A, Szasz AM, Dank M. High Tumor-Infiltrating Lymphocyte Count Is Associated with Distinct Gene Expression Profile and Longer Patient Survival in Advanced Ovarian Cancer. Int J Mol Sci 2023; 24:13684. [PMID: 37761986 PMCID: PMC10530512 DOI: 10.3390/ijms241813684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 08/26/2023] [Accepted: 09/03/2023] [Indexed: 09/29/2023] Open
Abstract
Cancer-related immunity plays a significant role in the outcome of ovarian cancer, but the exact mechanisms are not fully explored. A retrospective, real-life observational study was conducted including 57 advanced ovarian cancer patients. Immunohistochemistry for CD4+, CD8+, and CD45+ was used for assessing tumor-infiltrating immune cells. Furthermore, an immune-related gene expression assay was performed on 12-10 samples from patients with less than and more than 1-year overall survival (OS), respectively. A higher number of CD4+ (p = 0.0028) and CD45+ (p = 0.0221) immune cells within the tumor microenvironment were associated with longer OS of patients. In a multivariate setting, higher CD4+ T cell infiltration predicted longer OS (p = 0.0392). Twenty-three differentially expressed genes-involved in antigen presentation, costimulatory signaling, matrix remodeling, metastasis formation, and myeloid cell activity-were found when comparing the prognostic groups. It was found that tumor-infiltrating immune cell counts are associated with peculiar gene expression patterns and bear prognostic information in ovarian cancer. SOX11 expression emerged and was validated as a predictive marker for OS.
Collapse
Affiliation(s)
- Andras Jozsef Barna
- Department of Obstetrics and Gynecology, Saint Pantaleon Hospital, H-2400 Dunaujvaros, Hungary
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| | - Zoltan Herold
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| | - Miklos Acs
- Department of Surgery, University Hospital, D-93053 Regensburg, Germany
| | - Sandor Bazsa
- Department of Obstetrics and Gynecology, Saint Pantaleon Hospital, H-2400 Dunaujvaros, Hungary
| | - Jozsef Gajdacsi
- Directorate General of Medical Quality Assurance, Semmelweis University, H-1085 Budapest, Hungary
| | - Tamas Marton Garay
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
- Faculty of Information Technology and Bionics, Pazmany Peter Catholic University, H-1083 Budapest, Hungary
| | - Magdolna Herold
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
- Department of Internal Medicine and Hematology, Semmelweis University, H-1088 Budapest, Hungary
| | - Lilla Madaras
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary
| | - Dorottya Muhl
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| | - Akos Nagy
- Department of Pathology and Experimental Cancer Research, Semmelweis University, H-1085 Budapest, Hungary
| | - Attila Marcell Szasz
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| | - Magdolna Dank
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| |
Collapse
|
3
|
Dank M, Mühl D, Pölhös A, Csanda R, Herold M, Kovacs AK, Madaras L, Kulka J, Palhazy T, Tokes AM, Toth M, Ujhelyi M, Szasz AM, Herold Z. The Prediction Analysis of Microarray 50 (PAM50) Gene Expression Classifier Utilized in Indeterminate-Risk Breast Cancer Patients in Hungary: A Consecutive 5-Year Experience. Genes (Basel) 2023; 14:1708. [PMID: 37761848 PMCID: PMC10530528 DOI: 10.3390/genes14091708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 08/24/2023] [Accepted: 08/26/2023] [Indexed: 09/29/2023] Open
Abstract
BACKGROUND Breast cancer has been categorized into molecular subtypes using immunohistochemical staining (IHC) and fluorescence in situ hybridization (FISH) since the early 2000s. However, recent research suggests that gene expression testing, specifically Prosigna® Prediction Analysis of Microarray 50 (PAM50), provides more accurate classification methods. In this retrospective study, we compared the results of IHC/FISH and PAM50 testing. We also examined the impact of various PAM50 parameters on overall survival (OS) and progression-free survival (PFS). RESULTS We analyzed 42 unilateral breast cancer samples, with 18 classified as luminal A, 10 as luminal B, 8 as Human epidermal growth factor receptor 2 (HER2)-positive, and 6 as basal-like using PAM50. Interestingly, 17 out of the 42 samples (40.47%) showed discordant results between histopathological assessment and the PAM50 classifier. While routine IHC/FISH resulted in classification differences for a quarter to a third of samples within each subtype, all basal-like tumors were misclassified. Hormone receptor-positive tumors (hazard rate: 8.7803; p = 0.0085) and patients who had higher 10-year recurrence risk scores (hazard rate: 1.0539; p = 0.0201) had shorter OS and PFS. CONCLUSIONS Our study supports the existing understanding of molecular subtypes in breast cancer and emphasizes the overlap between clinical characteristics and molecular subtyping. These findings underscore the value of gene expression profiling, such as PAM50, in improving treatment decisions for breast cancer patients.
Collapse
Affiliation(s)
- Magdolna Dank
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| | - Dorottya Mühl
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| | - Annamária Pölhös
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| | - Renata Csanda
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| | - Magdolna Herold
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
- Department of Internal Medicine and Hematology, Semmelweis University, H-1088 Budapest, Hungary
| | - Attila Kristof Kovacs
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary
| | - Lilla Madaras
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary
| | - Janina Kulka
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary
| | - Timea Palhazy
- Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, H-1082 Budapest, Hungary
| | - Anna-Maria Tokes
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, H-1091 Budapest, Hungary
| | - Monika Toth
- Department of Radiology, Semmelweis University, H-1082 Budapest, Hungary
| | | | - Attila Marcell Szasz
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| | - Zoltan Herold
- Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, H-1083 Budapest, Hungary
| |
Collapse
|
4
|
Pipek O, Alpár D, Rusz O, Bödör C, Udvarnoki Z, Medgyes-Horváth A, Csabai I, Szállási Z, Madaras L, Kahán Z, Cserni G, Kővári B, Kulka J, Tőkés AM. Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort. Int J Mol Sci 2023; 24:ijms24108553. [PMID: 37239898 DOI: 10.3390/ijms24108553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 04/24/2023] [Accepted: 04/27/2023] [Indexed: 05/28/2023] Open
Abstract
A limited number of studies have focused on the mutational landscape of breast cancer in different ethnic populations within Europe and compared the data with other ethnic groups and databases. We performed whole-genome sequencing of 63 samples from 29 Hungarian breast cancer patients. We validated a subset of the identified variants at the DNA level using the Illumina TruSight Oncology (TSO) 500 assay. Canonical breast-cancer-associated genes with pathogenic germline mutations were CHEK2 and ATM. Nearly all the observed germline mutations were as frequent in the Hungarian breast cancer cohort as in independent European populations. The majority of the detected somatic short variants were single-nucleotide polymorphisms (SNPs), and only 8% and 6% of them were deletions or insertions, respectively. The genes most frequently affected by somatic mutations were KMT2C (31%), MUC4 (34%), PIK3CA (18%), and TP53 (34%). Copy number alterations were most common in the NBN, RAD51C, BRIP1, and CDH1 genes. For many samples, the somatic mutational landscape was dominated by mutational processes associated with homologous recombination deficiency (HRD). Our study, as the first breast tumor/normal sequencing study in Hungary, revealed several aspects of the significantly mutated genes and mutational signatures, and some of the copy number variations and somatic fusion events. Multiple signs of HRD were detected, highlighting the value of the comprehensive genomic characterization of breast cancer patient populations.
Collapse
Affiliation(s)
- Orsolya Pipek
- Department of Physics of Complex Systems, Institute of Physics, Eötvös Loránd University, 1117 Budapest, Hungary
| | - Donát Alpár
- HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary
| | - Orsolya Rusz
- Department of Pathology, Forensic and Insurance Medicine, SE NAP, Brain Metastasis Research Group, Semmelweis University, 1091 Budapest, Hungary
| | - Csaba Bödör
- HCEMM-SE Molecular Oncohematology Research Group, Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary
| | - Zoltán Udvarnoki
- Department of Physics of Complex Systems, Institute of Physics, Eötvös Loránd University, 1117 Budapest, Hungary
| | - Anna Medgyes-Horváth
- Department of Physics of Complex Systems, Institute of Physics, Eötvös Loránd University, 1117 Budapest, Hungary
| | - István Csabai
- Department of Physics of Complex Systems, Institute of Physics, Eötvös Loránd University, 1117 Budapest, Hungary
| | - Zoltán Szállási
- Department of Pathology, Forensic and Insurance Medicine, SE NAP, Brain Metastasis Research Group, Semmelweis University, 1091 Budapest, Hungary
- Computational Health Informatics Program (CHIP), Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA
- Danish Cancer Society Research Center, 2100 Copenhagen, Denmark
| | - Lilla Madaras
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, 1091 Budapest, Hungary
| | - Zsuzsanna Kahán
- Department of Oncotherapy, University of Szeged, 6720 Szeged, Hungary
| | - Gábor Cserni
- Department of Pathology, Albert Szent-Györgyi Medical Centre, University of Szeged, 6720 Szeged, Hungary
- Department of Pathology, Bács-Kiskun County Teaching Hospital, 6000 Kecskemét, Hungary
| | - Bence Kővári
- Department of Pathology, Albert Szent-Györgyi Medical Centre, University of Szeged, 6720 Szeged, Hungary
- Department of Pathology, Henry Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | - Janina Kulka
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, 1091 Budapest, Hungary
| | - Anna Mária Tőkés
- Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, 1091 Budapest, Hungary
| |
Collapse
|
5
|
Keszthelyi M, Bakos M, Szabó I, Török M, Lőczi L, Madaras L, Ács N, Várbíró S. [Molar pregnancy in postmenopause]. Orv Hetil 2023; 164:273-277. [PMID: 36806108 DOI: 10.1556/650.2023.32704] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Accepted: 12/11/2022] [Indexed: 02/23/2023]
Abstract
Hydatidiform mole is an extremely rare gestational trophoblastic disease. The pathogenesis is unique in that the maternal tumor arises from pregnancy tissue. In terms of occurrence, it mainly affects women of reproductive age. In our case report, a 53-year-old female patient was diagnosed with molar pregnancy as the background of her perimenopausal bleeding disorder. Mola is a high-risk disease because the symptoms can be deceiving and may be very similar to those of an incomplete miscarriage, ectopic pregnancy or perimenopausal bleeding. Appropriate diagnosis is key to terminating the pregnancy as soon as possible. The purpose of our case report is to draw attention to the atypical appearance of molar pregnancy; in relation to our perimenopausal female patient, we review the basic principles of treatment of hydatidiform mole and present the diagnostic and therapeutic management of a successfully completed case. Orv Hetil. 2023; 164(7): 273-277.
Collapse
Affiliation(s)
- Márton Keszthelyi
- 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Szülészeti és Nőgyógyászati Klinika Budapest, Üllői út 78/A, 1082 Magyarország
| | - Marcell Bakos
- 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Szülészeti és Nőgyógyászati Klinika Budapest, Üllői út 78/A, 1082 Magyarország
| | - István Szabó
- 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Szülészeti és Nőgyógyászati Klinika Budapest, Üllői út 78/A, 1082 Magyarország
| | - Marianna Török
- 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Szülészeti és Nőgyógyászati Klinika Budapest, Üllői út 78/A, 1082 Magyarország
| | - Lotti Lőczi
- 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Szülészeti és Nőgyógyászati Klinika Budapest, Üllői út 78/A, 1082 Magyarország
| | - Lilla Madaras
- 2 Semmelweis Egyetem, Általános Orvostudományi Kar, Patológiai, Igazságügyi és Biztosítási Orvostani Intézet Budapest Magyarország
| | - Nándor Ács
- 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Szülészeti és Nőgyógyászati Klinika Budapest, Üllői út 78/A, 1082 Magyarország
| | - Szabolcs Várbíró
- 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Szülészeti és Nőgyógyászati Klinika Budapest, Üllői út 78/A, 1082 Magyarország
| |
Collapse
|
6
|
Abstract
Papillary lesions of the breast represent a heterogeneous group of lesions including benign papillomas, papillomas with focal epithelial atypia, fully fledged ductal carcinoma in situ (DCIS) or lobular neoplasia, papillary DCIS, encapsulated papillary carcinomas without or with invasion, solid papillary carcinomas, and invasive papillary carcinomas. A micropapillary pattern characterized by lack of fibrous stalks within the papillae is observed in micropapillary DCIS and invasive micropapillary carcinoma. In addition, a variety of other rare breast lesions reveals a papillary architecture such as tall cell carcinoma with reversed polarity (TCCRP) and mucinous cystadenocarcinoma, adenomyoepithelioma, and secretory carcinoma. In addition, benign lesions such as usual ductal hyperplasia, apocrine metaplasia, gynecomastia, and juvenile papillomatosis may show a papillary or micropapillary architecture. Fragments of a benign papilloma in a breast biopsy are considered a lesion of uncertain malignant potential (B3 in the European classification) and excision is mostly recommended. Although the knowledge about molecular pathology of papillary breast lesions has increased, there is not sufficient evidence for diagnostically useful molecular features, yet. The aim of this review is to provide an update on papillary and micropapillary lesions with emphasis on problematic areas for daily diagnostic work including biopsies.
Collapse
Affiliation(s)
- Janina Kulka
- 2nd Department of Pathology, Semmelweis University, Üllői út 93, 1091, Budapest, Hungary, E.U..
| | - Lilla Madaras
- 2nd Department of Pathology, Semmelweis University, Üllői út 93, 1091, Budapest, Hungary, E.U.,Department of Pathology, Uzsoki Hospital, Budapest, Hungary
| | - Giuseppe Floris
- Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research, KU Leuven, University of Leuven, University Hospitals Leuven, Leuven, Belgium
| | - Sigurd F Lax
- Department of Pathology, Hospital Graz II, Graz, Austria.,School of Medicine, Johannes Kepler University, Linz, Austria
| |
Collapse
|
7
|
Tokes AM, Rusz O, Pollner-Szundi C, Madaras L, Kovács A, Molnár BI, Vári-Kakas S, Kulka J. Correction to: Abstracts : 31 st European Congress of Pathology. Virchows Arch 2019; 475:801. [PMID: 31667595 PMCID: PMC7608290 DOI: 10.1007/s00428-019-02688-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- A M Tokes
- 2nd Department of Pathology, Semmelweis University Budapest, Budapest, Hungary.
| | - O Rusz
- 2nd Department of Pathology, Semmelweis University Budapest, Budapest, Hungary
| | - C Pollner-Szundi
- 2nd Department of Pathology, Semmelweis University Budapest, Budapest, Hungary
| | - L Madaras
- 2nd Department of Pathology, Semmelweis University Budapest, Budapest, Hungary
| | - A Kovács
- 2nd Department of Pathology, Semmelweis University Budapest, Budapest, Hungary
| | - B I Molnár
- 1st Department of Surgery, Semmelweis University Budapest, Budapest, Hungary
| | - S Vári-Kakas
- Department of Computers and Information Technology, University of Oradea, Oradea, Romania
| | - J Kulka
- 2nd Department of Pathology, Semmelweis University Budapest, Budapest, Hungary
| |
Collapse
|
8
|
Ágoston EI, Somorácz Á, Madaras L, Zaránd A, Szentmártoni G, Orosz Z, Dank M, Baranyai Z. Successful treatment of three synchronous primary malignant tumours-reflection on surgical, pathological and oncological aspects and decision making. J Surg Case Rep 2018; 2018:rjy041. [PMID: 29657704 PMCID: PMC5890479 DOI: 10.1093/jscr/rjy041] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2017] [Accepted: 03/09/2018] [Indexed: 01/01/2023] Open
Abstract
We report a case of a patient with triple synchronous primary malignancies (breast, colon, kidney) which has not been previously reported in the literature. A 70-year-old woman was diagnosed with invasive ductal carcinoma of the left breast with axillary lymph node metastasis. During the staging period, renal cell carcinoma on the left kidney and mucinous adenocarcinoma in the proximal colon were found. Since the breast tumour demonstrated favourable biology, aromatase inhibitor therapy had been started and simultaneous right colectomy and left nephrectomy was performed. Six months after the first diagnosis, left sector excision and axillary block dissection were performed. Adjuvant FEC chemotherapy was administered, followed by radiotherapy. During the 16-month follow-up period disease recurrence was not detected.
Collapse
Affiliation(s)
- Emese Irma Ágoston
- 1st Department of Surgery, Semmelweis University, 78 Üllői út, 1082 Budapest, Hungary
| | - Áron Somorácz
- 2nd Institution of Pathology, Semmelweis University, 93 Üllői út, Budapest 1091, Hungary
| | - Lilla Madaras
- 2nd Institution of Pathology, Semmelweis University, 93 Üllői út, Budapest 1091, Hungary
| | - Attila Zaránd
- 1st Department of Surgery, Semmelweis University, 78 Üllői út, 1082 Budapest, Hungary
| | | | - Zsuzsanna Orosz
- Cancer Center, Semmelweis University, 78/a Üllői út, 1082 Budapest, Hungary
| | - Magdolna Dank
- Cancer Center, Semmelweis University, 78/a Üllői út, 1082 Budapest, Hungary
| | - Zsolt Baranyai
- 1st Department of Surgery, Semmelweis University, 78 Üllői út, 1082 Budapest, Hungary
| |
Collapse
|
9
|
Ács B, Madaras L, Kovács KA, Micsik T, Tőkés AM, Győrffy B, Kulka J, Szász AM. Reproducibility and Prognostic Potential of Ki-67 Proliferation Index when Comparing Digital-Image Analysis with Standard Semi-Quantitative Evaluation in Breast Cancer. Pathol Oncol Res 2017; 24:115-127. [DOI: 10.1007/s12253-017-0220-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Accepted: 03/30/2017] [Indexed: 01/24/2023]
|
10
|
Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G, Tőkés T, Molnár BÁ, Molnár IA, Vári-Kakas S, Kulka J, Tőkés AM. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. Diagn Pathol 2017; 12:20. [PMID: 28222768 PMCID: PMC5320658 DOI: 10.1186/s13000-017-0608-5] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Accepted: 02/02/2017] [Indexed: 01/06/2023] Open
Abstract
BACKGROUND Studies have partly demonstrated the clinical validity of Ki-67 as a predictive marker in the neoadjuvant setting, but the question of the best cut-off points as well as the importance of this marker as a prognostic factor in partial responder/non-responder groups remains uncertain. METHODS One hundred twenty patients diagnosed with invasive breast cancer and treated with neoadjuvant chemotherapy (NAC) between 2002 and 2013 were retrospectively recruited to this study. The optimal cut-off value for Ki-67 labeling index (LI) to discriminate response to treatment was assessed by receiver operating characteristic (ROC) curve analysis. Kaplan-Meier curve estimation, log-rank test and cox regression analysis were carried out to reveal the association between Ki-67 categories and survival (DMFS = Distant metastases-free survival, OS = Overall survival). RESULTS Twenty three out of 120 patients (19.2%) achieved pathologic complete remission (pCR), whereas partial remission (pPR) and no response (pNR) to neoadjuvant chemotherapy (NAC) was detected in 60.8% and 20.0%, respectively. The distribution of subtypes showed a significant difference in pathological response groups (p < 0.001). Most of the TNBC cases were represented in pCR group. The most relevant cut-off value for the Ki-67 distinguishing pCR from pNR cases was 20% (p = 0.002). No significant threshold for Ki-67 was found regarding DMFS (p = 0.208). Considering OS, the optimal cut-off point occurred at 15% Ki-67 (p = 0.006). The pPR group represented a significant Ki-67 threshold at 30% regarding OS (p = 0.001). Ki-67 and pPR subgroups were not significantly associated (p = 0.653). For prognosis prediction, Ki-67 at 30% cut-off value (p = 0.040) furthermore subtype (p = 0.037) as well as pathological response (p = 0.044) were suitable to separate patients into good and unfavorable prognosis cohorts regarding OS. However, in multivariate analyses, only Ki-67 at 30% threshold (p = 0.029), and subtype (p = 0.008) were independently linked to OS. CONCLUSIONS NAC is more efficient in tumors with at least 20% Ki-67 LI. Both Ki-67 LI and subtype showed a significant association with pathological response. Ki-67 LI represented independent prognostic potential to OS in our neoadjuvant patient cohort, while pathological response did not. Additionally, our data also suggest that if a tumor is non-responder to NAC, increased Ki-67 is a poor prognostic marker.
Collapse
Affiliation(s)
- Balázs Ács
- 2nd Department of Pathology, Semmelweis University, 1091, Budapest, Üllői út 93, Hungary
| | - Veronika Zámbó
- 2nd Department of Pathology, Semmelweis University, 1091, Budapest, Üllői út 93, Hungary
| | - Laura Vízkeleti
- 2nd Department of Pathology, Semmelweis University, 1091, Budapest, Üllői út 93, Hungary.,MTA-SE-NAP Brain Metastasis Research Group, Semmelweis University, Budapest, Hungary
| | - A Marcell Szász
- 2nd Department of Pathology, Semmelweis University, 1091, Budapest, Üllői út 93, Hungary.,MTA-TTK Lendület Cancer Biomarker Research Group, 1091, Budapest, Üllői út 93, Hungary
| | - Lilla Madaras
- 2nd Department of Pathology, Semmelweis University, 1091, Budapest, Üllői út 93, Hungary
| | - Gyöngyvér Szentmártoni
- Department of Clinical Oncology, Semmelweis University, 1083, Budapest, Tömő uta 25-29, Hungary
| | - Tímea Tőkés
- Department of Clinical Oncology, Semmelweis University, 1083, Budapest, Tömő uta 25-29, Hungary
| | - Béla Á Molnár
- 1st Department of Surgery, Semmelweis University, 1082, Budapest Üllői út 78, Hungary
| | - István Artúr Molnár
- 1st Department of Surgery, Semmelweis University, 1082, Budapest Üllői út 78, Hungary
| | - Stefan Vári-Kakas
- University of Oradea, Romania, Faculty of Electrical Engineering and Information Technology, Str. Universitatii nr. 1, Oradea, Romania
| | - Janina Kulka
- 2nd Department of Pathology, Semmelweis University, 1091, Budapest, Üllői út 93, Hungary
| | - Anna-Mária Tőkés
- 2nd Department of Pathology, Semmelweis University, 1091, Budapest, Üllői út 93, Hungary. .,MTA-SE Tumor Progression Research Group, Semmelweis University, 2nd Department of Pathology, 1091 Budapest, Üllői út 93, Hungary.
| |
Collapse
|
11
|
Tőkés T, Tőkés AM, Szentmártoni G, Kiszner G, Madaras L, Kulka J, Krenács T, Dank M. Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer. Virchows Arch 2016; 468:675-86. [PMID: 27026269 DOI: 10.1007/s00428-016-1925-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Revised: 11/16/2015] [Accepted: 03/07/2016] [Indexed: 12/18/2022]
Abstract
We aimed to analyze to what extent expression of four cell cycle regulation markers-minichromosome maintenance protein (MCM2), Ki-67, cyclin A, and phosphohistone-H3 (PHH3)-predict response to primary systemic therapy in terms of pathological complete remission (pCR). In search of an accurate and reproducible scoring method, we compared computer-assisted (CA) and routine visual assessment (VA) of immunoreactivity. We included 57 patients with breast cancer in the study. The cell cycle markers were detected using immunohistochemistry on pre-therapy core biopsy samples. Parallel CA (validated by manual labeling) and standard VA were performed and compared for diagnostic agreement and predictive value for pCR. CA and VA results were dichotomized based on receiver operating characteristic analysis defined optimal cut-off values. "High" was defined by staining scores above the optimal cut-off, while "low" had staining scores below the optimal cut-off. The CA method resulted in significantly lower values for Ki-67 and MCM2 compared to VA (mean difference, -3.939 and -4.323). Diagnostic agreement was highest for cyclin A and PHH3 (-0.586 and -0.666, respectively). Regardless of the method (CA/VA) used, all tested markers were predictive of pCR. Optimal cut-off-based dichotomization improved diagnostic agreement between the CA and VA methods for every marker, in particular for MCM2 (κ = 1, p < 0.000). Cyclin A displayed excellent agreement (κ = 0.925; p < 0.000), while Ki-67 and PHH3 showed good agreement (κ = 0.789, p < 0.000 and κ = 0.794, p < 0.000, respectively). We found all cell cycle markers (Ki-67, MCM2, cyclin A, and PHH3) predictive of pCR. Diagnostic agreement between CA and VA was better at lower staining scores but improved after optimal cut-off-based dichotomization.
Collapse
Affiliation(s)
- Tímea Tőkés
- 1st Department of Internal Medicine, Oncological Division, Semmelweis University, Tömő utca 25-29, 4th floor, Budapest, 1083, Hungary
| | - Anna-Mária Tőkés
- MTA-SE Tumor Progression Research Group, 2nd Department of Pahtology, Semmelweis University, Üllői út 93, Budapest, 1091, Hungary.,2nd Department of Pathology, Semmelweis University, Üllői út 93, Budapest, 1091, Hungary
| | - Gyöngyvér Szentmártoni
- 1st Department of Internal Medicine, Oncological Division, Semmelweis University, Tömő utca 25-29, 4th floor, Budapest, 1083, Hungary
| | - Gergő Kiszner
- 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, Budapest, 1085, Hungary
| | - Lilla Madaras
- 2nd Department of Pathology, Semmelweis University, Üllői út 93, Budapest, 1091, Hungary
| | - Janina Kulka
- 2nd Department of Pathology, Semmelweis University, Üllői út 93, Budapest, 1091, Hungary
| | - Tibor Krenács
- MTA-SE Tumor Progression Research Group, 2nd Department of Pahtology, Semmelweis University, Üllői út 93, Budapest, 1091, Hungary.,1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Üllői út 26, Budapest, 1085, Hungary
| | - Magdolna Dank
- 1st Department of Internal Medicine, Oncological Division, Semmelweis University, Tömő utca 25-29, 4th floor, Budapest, 1083, Hungary.
| |
Collapse
|
12
|
Acs B, Szekely N, Szasz AM, Lotz G, Szekely T, Istok R, Szekely E, Madaras L, Kulka J, Jaray B. Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study. Diagn Cytopathol 2016; 44:466-71. [DOI: 10.1002/dc.23463] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 01/15/2016] [Accepted: 02/12/2016] [Indexed: 11/09/2022]
Affiliation(s)
- Balazs Acs
- 2nd Department of Pathology; Semmelweis University; Budapest Hungary
| | - Nora Szekely
- 2nd Department of Pathology; Semmelweis University; Budapest Hungary
| | | | - Gabor Lotz
- 2nd Department of Pathology; Semmelweis University; Budapest Hungary
| | - Tamas Szekely
- 2nd Department of Pathology; Semmelweis University; Budapest Hungary
| | - Roland Istok
- 2nd Department of Pathology; Semmelweis University; Budapest Hungary
| | - Eszter Szekely
- 2nd Department of Pathology; Semmelweis University; Budapest Hungary
| | - Lilla Madaras
- 2nd Department of Pathology; Semmelweis University; Budapest Hungary
| | - Janina Kulka
- 2nd Department of Pathology; Semmelweis University; Budapest Hungary
| | - Balazs Jaray
- 2nd Department of Pathology; Semmelweis University; Budapest Hungary
| |
Collapse
|
13
|
Acs B, Madaras L, Kovacs KA, Tokes AM, Kulka J, Szasz AM. Abstract P1-01-02: Ki-67 proliferation index supported by digital quantitation in breast cancer: A comparative study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: In cases of breast cancer, in addition to hormone receptor and Her2 status, proliferation markers (mitotic index, Ki-67 proliferation index = KIPI) also have therapeutic implications. The 2013 St. Gallen consensus guideline includes 14% cut-off point (20% by many experts) for KIPI to distinguish luminal A-like and luminal B-like subtypes, that might be associated with remarkable intra-/interobsever variability applied in daily pathological routine utilizing semiquantitative (SQ) "eye-balling" method.
Objective: The comparison of conventional SQ method and digital image-analysis (DIA) processes for the detection of KIPI.
Methods: Three hundred and forty-seven breast cancer patients' samples with 99.24 months median follow-up data were included in our study (ethical approval: IKEB #7/2008 and 7-1/2008). Tissue microarrays (TMA) were prepared from the representative paraffin-embedded tumor blocks. After performing Ki-67 (MIB1 clone, #0505 by iOT on Ventana Benchmark XT autostainer by Roche) immunoreaction, conventional evaluation of KIPI was performed by 3 breast pathologists independently (SQ1-3). Digital image analysis was supported by PatternQuant (Pannoramic Viewer v15.3 and QuantCenter 2.0, 3DHistech Ltd.) applying a fully automatic tumor tissue recognition module with KIPI detection (DIA-1), and an adjustable module (DIA-2) with the possibility of manual corrections to exclude false detections. Interobserver variability was estimated with intra-class correlation coefficient (ICC). Digital pathological methods were compared to the - currently gold standard - SQ determination of KIPI using SPSS 22 statistical program.
Results: The three pathologists' SQ evaluations demonstrated a remarkable concordance (ICC=0.889; 95% CI= 0.834-0.922). A reference KIPI value (KIPI-RV) was derived from mean values of SQ2 and SQ3, since no significant difference was found between them (p=0.617). KIPI-RV and DIA-2 showed no significant difference (p=0.754), and excellent concordance (ICC=0.979; 95% CI=0.975-0.982). Significant difference has occurred between KIPI-RV and results of DIA-1 (p=0.001). Upon dichotomizing KIPI value at 14%, no significant difference was found between KIPI-RV and DIA-2 (p=0.262), while KIPI-RV and DIA-1 differed (p=0.006). For prognosis prediction, all three methods were able to perform statistically significant division of our patients into 2 cohorts with distinct DFS at 14% (p<0.017-0.038). At 20% threshold of KIPI, DIA-1 failed (p=0.053), while KIPI-RV and DIA-2 were able to separate good and unfavorable prognosis patients' cohorts (p=0.01; p=0.004).
Conclusion: The DIA processes are objective methods in the evaluation of KIPI. The fully automated DIA-1 method differed most from SQ results. Digital image analysis adjusted by a pathologist (our DIA-2 method) reached high concordance with results of SQ. Further refinement and validation are needed to verify applicability of automatic tumor pattern recognition software in diagnostic practice. Our results confirm that SQ evaluation of KIPI is reliable.
This study was supported by the research grant from Hungarian Society of Medical Oncology 2014 and research grant from Doctoral School of Ph.D. Studies, Semmelweis University 2014.
Citation Format: Acs B, Madaras L, Kovacs KA, Tokes A-M, Kulka J, Szasz AM. Ki-67 proliferation index supported by digital quantitation in breast cancer: A comparative study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-01-02.
Collapse
Affiliation(s)
- B Acs
- Semmelweis University, Budapest, Pest, Hungary
| | - L Madaras
- Semmelweis University, Budapest, Pest, Hungary
| | - KA Kovacs
- Semmelweis University, Budapest, Pest, Hungary
| | - A-M Tokes
- Semmelweis University, Budapest, Pest, Hungary
| | - J Kulka
- Semmelweis University, Budapest, Pest, Hungary
| | - AM Szasz
- Semmelweis University, Budapest, Pest, Hungary
| |
Collapse
|
14
|
Kulka J, Tõkés AM, Madaras L, Kovács A, Ács B, Illyés I, Kiss O, Székely B, Lotz G, Szász MA. [Clinico-pathologically focused breast cancer research]. Magy Onkol 2015; 59:286-291. [PMID: 26665188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Accepted: 10/12/2015] [Indexed: 06/05/2023]
Abstract
In the second half of the 20th century research focusing to breast carcinomas at the Semmelweis University had been mostly linked to the 2nd Department of Pathology. Nowadays, following the rapidly improving treatment modalities in breast cancer there is an increasing need for defining new predictive and prognostic markers. The modern molecular pathological approach helps tremendously in mapping the biological behavior of individual cases of breast cancers and meanwhile, it is one of the prerequisites of a more efficient treatment both in neoadjuvant and adjuvant settings, as well as in metastatic disease. We provide a brief review of the relevant results we have obtained in breast cancer research between 2000 and 2015.
Collapse
Affiliation(s)
- Janina Kulka
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Anna-Mária Tõkés
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Lilla Madaras
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Attila Kovács
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Balázs Ács
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Ildikó Illyés
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Orsolya Kiss
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Borbála Székely
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Gábor Lotz
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Marcell A Szász
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| |
Collapse
|
15
|
Madaras L, Balint N, Gyorffy B, Tokes AM, Barshack I, Yosepovich A, Friedman E, Paluch-Shimon S, Zippel D, Baghy K, Timar J, Kovalszky I, Kulka J, Szasz AM. BRCA Mutation-Related and Claudin-Low Breast Cancer: Blood Relatives or Stepsisters? Pathobiology 2015; 83:1-12. [DOI: 10.1159/000439135] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2015] [Accepted: 08/03/2015] [Indexed: 11/19/2022] Open
|
16
|
Madaras L, Szirtes I, Bata P, Riesz P, Somorácz A, Székely E, Romics M, Majoros A, Borka K, Szász MA, Nyirády P. [Significance of positive surgical margin in radical prostatectomy]. Magy Onkol 2014; 58:204-210. [PMID: 25260085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2014] [Accepted: 08/12/2014] [Indexed: 06/03/2023]
Abstract
The optimal oncological result of radical prostatectomy (RP) is complete removal of the prostate gland and seminal vesicles with negative surgical margins. Preoperative diagnostic biopsies are examined and reported by the pathologist according to standardized rules. Staging of the disease is based on modern preoperative image analysis, most commonly multiparametric MRI. Pathological assessment and reporting of RP specimens is based on the International Society of Uropathology guidelines issued by the 2009 Consensus Conference. Positive surgical margin (PSM) is reported by the pathologist in approximately 1/3rd of RP cases. PSM increases the risk of biochemical, local and systemic progression. Pseudo-whole mount assessment of these specimens is the basis for radio-pathological correlation, thus providing quality control for preoperative MRI as well as assisting preoperative image analysis, sampling and diagnostic workup.
Collapse
Affiliation(s)
- Lilla Madaras
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Ildikó Szirtes
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Pál Bata
- Radiológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
| | - Péter Riesz
- Urológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
| | - Aron Somorácz
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Eszter Székely
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Miklós Romics
- Urológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
| | - Attila Majoros
- Urológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
| | - Katalin Borka
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Marcell A Szász
- II. Sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary.
| | - Péter Nyirády
- Urológiai Klinika, Semmelweis Egyetem, Budapest, Hungary
| |
Collapse
|
17
|
Madaras L, Kovács KA, Szász AM, Kenessey I, Tőkés AM, Székely B, Baranyák Z, Kiss O, Dank M, Kulka J. Clinicopathological Features and Prognosis of Pregnancy Associated Breast Cancer – A Matched Case Control Study. Pathol Oncol Res 2013; 20:581-90. [DOI: 10.1007/s12253-013-9735-9] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2013] [Accepted: 12/05/2013] [Indexed: 12/14/2022]
|
18
|
Tokes AM, Szasz AM, Kovács AK, Juhasz E, Nemeth Z, Baranyai Z, Madaras L, Kulka J. Abstract P3-05-08: Analysis of the expression of claudin-3, -4, -7 and E-cadherin in breast cancer: are they surrogates for the claudin-low subtype? Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p3-05-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The molecular architecture of tight junctions (TJ) has been a subject of extensive studies in a number of malignancies. Among the TJ components, the members of the protein family claudins (CLDN) have been found to be differentially expressed correlating with histological grade (HG) in a number of tissues. Furthermore, the expression of these junctional proteins (JP) have recently been implied in the identification of the claudin-low subtype by gene expression analysis.
Material and methods: 261 breast cancer specimens diagnosed between 1999 and 2002 were collected and evaluated histopathologically and immunophenotypically by a single specialist. Tissue microarrays were constructed using a TMA-builder instrument (Histopathology Ltd., Pecs, Hungary). To identify the eventual prognostic role of the TJ proteins CLDN3, −4 and −7, and adherent junction protein E-cadherin (ECDH) their immunohistochemical (IHC) expression was analysed by 3 investigators separately, and a consensus score was reached. The IHC results were compared to the patients' follow-up data applying Kaplan-Meier analysis supported by log-rank test. Furthermore, we aimed at identifying the worse prognosis tumour group based on clustering of the expression of the above mentioned JPs.
Results: The expression of CLDN3 correlated with vascular invasion (VI)/p = 0.029/, necrosis (NC)/p = 0.001/, HG/p = 0.001/ and mitotic index (MI)/p = 0.022/. CLDN4 and CLDN7 correlated with NC/p = 0.001, p = 0.012, respectively/ and HG/p = 0.034, p = 0.001, respectively/, while ECDH correlated with HG/p = 0.001/ and MI/p = 0.001/.
In single protein analysis, groups displaying gradually increasing CLDN3, −7 and ECDH/p = 0.017/expression (split at mean expression ± SD) showed a trend of bearing poorer prognostic features. CLDN4, on the other hand, showed different tendency: gradually increasing expression also correlated with worse relapse-free survival (RFS), while CLDN4 negative/low tumors had the poorest prognosis/p = 0.034/.
In multiple protein analysis, groups were created using k-means clustering and the following cohorts were created - appearing in prognostic sequence starting with the longest RFS: ECDH-low groups with 1) low/n=31/ and 2) high/n=42/ CLDN3 expression; 3) CLDN7-low (CLDN3, -4 and ECDH-high) group/n=35/, 4) “all-high” expression group/n=70/; 5) CLDN3-low (CLDN4, -7 and ECDH-high) group/n=68/ and 6) “all-low” group/n=15/. The latter was characterised by the CLDN4-low feature as compared to the other groups.
Conclusion: Expression of JPs can have prognostic relevance in breast carcinomas. The groups with low expression of ECDH have good prognosis, while gradually increasing JP expression outlines poor prognostic tumours. Strikingly the drop in all JPs expression - most likely resembling the claudin-low subtype - specifies the subgroup with the poorest outcome, which still remains an infrequent disease entity.
Grant support: TÁMOP-4.2.2/B-10/1-2010-0013.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-05-08.
Collapse
Affiliation(s)
- A-M Tokes
- Semmelweis University, Budapest, Hungary; Uzsoki Memorial Hospital, Budapest, Hungary
| | - AM Szasz
- Semmelweis University, Budapest, Hungary; Uzsoki Memorial Hospital, Budapest, Hungary
| | - AK Kovács
- Semmelweis University, Budapest, Hungary; Uzsoki Memorial Hospital, Budapest, Hungary
| | - E Juhasz
- Semmelweis University, Budapest, Hungary; Uzsoki Memorial Hospital, Budapest, Hungary
| | - Z Nemeth
- Semmelweis University, Budapest, Hungary; Uzsoki Memorial Hospital, Budapest, Hungary
| | - Z Baranyai
- Semmelweis University, Budapest, Hungary; Uzsoki Memorial Hospital, Budapest, Hungary
| | - L Madaras
- Semmelweis University, Budapest, Hungary; Uzsoki Memorial Hospital, Budapest, Hungary
| | - J Kulka
- Semmelweis University, Budapest, Hungary; Uzsoki Memorial Hospital, Budapest, Hungary
| |
Collapse
|
19
|
Madaras L, Szász MA, Baranyák Z, Tõkés AM, Szittya L, Lotz G, Székely B, Szentmártoni G, Dank M, Baranyai Z, Kulka J. [Morphological and immunophenotypical heterogeneity in breast cancers of young and elderly women]. Magy Onkol 2012; 56:75-78. [PMID: 22629543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2010] [Accepted: 01/17/2012] [Indexed: 06/01/2023]
Abstract
There is a reasonable heterogeneity in the morphological appearance and the immunohistochemical properties of distinct breast tumors. Furthermore, it is also known that cancer arising in young women have different prognosis than the ones developing in the elderly. We analyzed breast tumors of 41 young (<35 years) and 33 older women (>65 years) regarding histopathological properties and immunohistochemical reactions for ER, PgR, HER2 and Ki-67, as well as HER2 FISH. The longest diameters, thus largest available surface areas of the tumors were included in the evaluation. Different regions were marked for morphology and in all immunohistochemical reactions. The regions in the distinct tumors showing different pathological and immunohistochemical appearance were identical (p<0.001). The number of morphologically different tumor regions were more frequent in tumors developing in the young (1.82 vs. 1.48 regions/tumor), and 53.6% of tumors with heterogeneous architecture were in young vs. 39.4% in the elderly. However, regarding HER2 staining, cancers in the young patients have shown greater variability among the different tumor areas (p=0.007). The origin of tumor cells predicting prognosis remains undetermined. Whether the analysis of the expression pattern of the whole tumor is conducted or the minute regions are separately examined and averaged, the same results can be achieved. With the development of molecular techniques and accurate prognostic and treatment information rendered to samples the question may be soon answered.
Collapse
Affiliation(s)
- Lilla Madaras
- II. sz. Patológiai Intézet, Semmelweis Egyetem, Budapest, Hungary
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Baranvak Z, Madaras L, Tokes A, Szász A, Szekely B, Kulka J. 5101 POSTER 86 Cases of Early-onset Breast Cancer in Hungary – Retrospective Analysis of Immunohistochemistry (IHC) and Family-history Data -Assessing the Risk of Carrying BRCA1 and BRCA2 Mutation. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71543-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Szasz A, Gyorffy B, Nemeth Z, Krenacs T, Baranyai Z, Harsanyi L, Dank M, Madaras L, Tokes A, Kulka J. 1438 POSTER Claudin-4/E-cadherin Index to Predict Prognosis in Breast Cancer. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70931-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
22
|
Szasz AM, Tokes AM, Micsinai M, Krenacs T, Jakab C, Lukacs L, Nemeth Z, Baranyai Z, Dede K, Madaras L, Kulka J. Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin Exp Metastasis 2010; 28:55-63. [PMID: 20963473 DOI: 10.1007/s10585-010-9357-5] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2009] [Accepted: 10/08/2010] [Indexed: 12/18/2022]
Abstract
Adherent and tight junction molecules have been described to contribute to carcinogenesis and tumor progression. Additionally, the group of claudin-low tumors have recently been identified as a molecular subgroup of breast carcinoma. In our study, we examined the expression pattern of claudins, beta-catenin and E-cadherin in invasive ductal (IDCs) and lobular (ILCs) carcinomas and their corresponding lymph node metastases (LNMs). Tissue microarrays of 97 breast samples (60 invasive ductal carcinomas, 37 invasive lobular carcinomas) and their corresponding LNMs have been analyzed immunohistochemically for claudin-1, -2, -3, -4, -5, -7, beta-catenin and E-cadherin expression. The stained slides were digitalized with a slide scanner and the reactions were evaluated semiquantitatively. When compared to LNMs, in the IDC group beta-catenin and claudin-2, -3, -4 and -7 protein expression showed different pattern while claudin-1, -2, -3, -4 and -7 were differently expressed in the ILC group. Lymph node metastases developed a notable increase of claudin-5 expression in both groups. Decrease or loss of claudin-1 and expression of claudin-4 in lymph node metastases correlated with reduced disease-free survival in our patients. According to our observations, the expression of epithelial junctional molecules, especially claudins, is different in primary breast carcinomas compared to their lymph node metastases as demonstrated by immunohistochemistry. Loss of claudin junctional molecules might contribute to tumor progression, and certain claudin expression pattern might be of prognostic relevance.
Collapse
Affiliation(s)
- A M Szasz
- 2nd Department of Pathology, Semmelweis University, Ulloi ut 93, Budapest 1091, Hungary.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Székely B, Madaras L, Szentmártoni G, Szász AM, Baranyák Z, Szittya L, Torgyík L, Zergényi E, Borbényi E, Kenessey I, Korompay A, Langmár Z, Bánhidy F, Kulka J, Dank M. [Comparison of breast cancer in young and old women based on clinicopathological features]. Magy Onkol 2010; 54:19-26. [PMID: 20350864 DOI: 10.1556/monkol.54.2010.1.3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The two far ends of the age at the diagnosis of breast cancer are the age of younger than 35, and that of older than 70. Most probably, these two groups of patients differ in many ways. The aim of our present study was to underline the fact that age at the diagnosis of breast cancer is indeed a prognostic factor. Between October 1995 and March 2009, 80 old and 51 young breast cancer patients were treated at the Department of Diagnostic Radiology and Oncotherapy, Semmelweis University, Budapest. The prognostic and predictive factors of the tumors were analysed together with the disease-free and overall survival data. There were statistically significant differences between the two groups concerning the menstrual and reproductive factors, histological characteristics and immunophenotype of the tumors. Tumor size, nodal status and the Nottingham Prognostic Index did not show statistically significant differences. A trend to a shorter disease-free survival, higher rate of distant metastases and disease-specific death was seen in the group of young patients, but it was not significant. Overall survival was significantly shorter in the group of young patients. Therefore, we can state that young patients have a more aggressive disease and worse outcome. There is an increased importance of self examination in these groups, since both age groups are beyond the age limits of the screening population in Hungary. The media and primary school education as well should be involved in educating women concerning this aspect. The individual follow-up of young patients with positive family history should also be established.
Collapse
Affiliation(s)
- Borbála Székely
- Semmelweis Egyetem, AOK, Radiológiai és Onkoterápiás Klinika, 1082 Budapest, Ulloi út 78/a.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Szasz A, Szasz A, Szasz A, Micsinai M, Tokes A, Tokes A, Madaras L, Krenacs T, Kulka J. Proteomic Profiling of Breast Carcinomas Based on Claudin Expression Pattern. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6123] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
INTRODUCTION. With the advent of molecular techniques, the UNC workgroup (Perou 2000) has identified at least five biologically distinct subtypes (luminal A, luminal B, Her2+, triple-negative, normal-like) with genomic characterization of human breast tumors. The same lab (Herschkowitz 2007) identified a new and rare molecular subtype of human breast cancer which is now being referred to as the claudin-low subgroup. In our study, we aimed to perform a thorough analysis of the claudin, beta-catenin and E-cadherin protein expression pattern in invasive ductal (IDCs) and lobular (ILCs) breast carcinomas of different grades, their corresponding lymph node metastases (LNMs) and normal adjacent tissues NATs). METHODS. Tissue microarrays of 98 samples (59 IDCs: 20 grade 3, 26 grade 2 and 13 grade 1; 39 ILCs: 8 grade 3, 24 grade 2 and 7 grade 1), their corresponding LNMs and NATs have been analyzed immunohistochemically for beta-catenin, claudin-1, -2, -3, -4, -5, -7 and E-cadherin expression. The stained slides were digitalized with a slide scanner and the reactions were evaluated semiquantitatively according to our previous practice (Kulka 2009). RESULTS. Based on our evaluation, we were able to conclude the following significant results: 1) There is a markedly different expression of beta-catenin, claudin-1, -3, -4 and -7 in normal and neoplastic tissues. 2) Claudin-1, -2 and E-cadherin are able to differentiate ductal and lobular invasive carcinomas. 3) In E-cadherin-negative IDCs beta-catenin and claudin-7 is expressed on lower levels than in the E-cadherin-positive IDCs. In E-cadherin-positive ILCs the beta-catenin, claudin-4 and -7 is expressed at higher levels than in E-cadherin-negative ILCs. 4) Claudin-1 and -2 protein expression in the molecular subtypes can also distinguish luminal subtypes from each other and the HER2+ and triple-negative group. 5) Claudin-3 and E-cadherin or claudin-4 and -7 are both able to separate a claudin-low subtype of tumors with confidence.This later subclass also expresses beta-catenin on a lower level than the others. 6) Hierarchical clustering of primary carcinomas based on claudin expression reflects proliferation rates of the primary tumors. 7) Beta-catenin, claudin-1, -2 can differentiate primary carcinomas and lymph node metastases. 8) Histological grade correlates with claudin-1, -4 and -7 expression. CONCLUSION. According to our observations, the expression of TJ molecules, especially claudins, are different in tumors compared to normal breast tissue. Also, we could identify a claudin-low tumor subtype based on the loss of claudin-4 and -7 expression. Certain claudins are also differently expressed in the lymph node metastases as demonstrated by immunohistochemistry. Claudin profile of breast tumors correlates with histopathological variables and most likely it reflects an important mechanism of cancer differentiation and progression.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6123.
Collapse
Affiliation(s)
- A. Szasz
- 1 Semmelweis University, Pest, Hungary
| | | | | | | | - A. Tokes
- 1 Semmelweis University, Pest, Hungary
| | - A. Tokes
- 5 Cancer Research UK, London Research Institute, United Kingdom
| | | | | | - J. Kulka
- 1 Semmelweis University, Pest, Hungary
| |
Collapse
|
25
|
Kulka J, Tokés AM, Tóth AI, Szász AM, Farkas A, Borka K, Járay B, Székely E, Istók R, Lotz G, Madaras L, Korompay A, Harsányi L, László Z, Rusz Z, Molnár BA, Molnár IA, Kenessey I, Szentmártoni G, Székely B, Dank M. [Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy]. Magy Onkol 2009; 53:335-343. [PMID: 20071305 DOI: 10.1556/monkol.53.2009.4.2] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The purpose of the study was to identify breast cancer subtypes by immunohistochemistry likely to respond to neoadjuvant chemotherapy and to analyze the used chemotherapy regimen and the range of response rates. Analysis of a collected database was performed. Ninety-two patients were identified in our files who received neoadjuvant chemotherapy between 1998 and 2009. We used immunohistochemical profiles (ER, PgR, HER2, Ki-67 and p53) of NCB, FNAB and surgical breast specimens to subclassify the tumors. Pathological response rates were assessed following surgical removal of tumors by using the Chevallier classification. DFS and OS was measured in 88 cases from the date of definitive surgery to the date of last follow-up or death. Pathological complete or near-complete remission (pCR = Chevallier I and II) was observed in 13 of 92 cases (14.1%). According to the preoperative characteristics of the 13 tumors achieving pCR, 9 of the cases were triple negative, one of 13 was ER-/HER2+ and three of 13 ER+/HER2+. Twenty-four of 92 patients received taxane based neoadjuvant chemotherapy, 30 of 92 anthracycline based neoadjuvant chemotherapy, 33 of 92 taxane + anthracycline regimen and 2 of 92 CMF regimen. In the taxane treated group of patients the pCR rate was 29.1%, in the anthracycline group 6.6% and in the taxane + anthracycline treated group 12.1%. Concerning DFS, significant difference was observed between the Chevallier III and IV groups (p=0.006), and less events were observed in the pCR group (not significant). pCR was associated with significantly better OS (p=0.050). It seems that even limited, routinely used immunohistochemical profiling of tumors is able to predict the likelihood of pCR to neoadjuvant chemotherapy. Patients with triple negative and HER2-positive cancers are likely to achieve pCR after neoadjuvant chemotherapy.
Collapse
Affiliation(s)
- Janina Kulka
- Semmelweis Egyetem II. sz. Patológiai Intézet 1091 Budapest Ulloi út 93.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
Hepatic angiomyolipomas are rare tumors, especially in comparison with those occurring in the kidney. Nevertheless, it is important to be aware of their existence, especially when occurring in the liver, where they might have different subtypes. Not infrequently they are composed of rather irregular cells with epithelioid appearance. In these cases hepatocellular carcinoma or the possibility of other malignant tumors has to be ruled out, with the aid of numerous immunohistochemical reactions. The authors present a case of a female patient, whose liver lesion was first diagnosed on cytological examination as a hepatocellular carcinoma. Based on the preoperative cytological diagnosis, a large liver lobe resection was performed. Histological examination found an angiomyolipoma of the above-mentioned type, and the final diagnosis was ascertained with the aid of vimentin, smooth muscle actin (SMA), and HMB-45.
Collapse
Affiliation(s)
- E Székely
- Semmelweis University, 2nd Department of Pathology, Budapest, H-1091, Hungary.
| | | | | | | | | |
Collapse
|
27
|
Abstract
Leiomyosarcomas of the breast are rare tumors. Less than 15 such cases have been reported in the literature so far. In this paper authors describe a case of leiomyosarcoma of a female breast presenting as a firm lobulated mass, mimicking a phylloid tumor radiographically. By fine needle aspiration biopsy, on the smears discohesive malignant looking cells were conclusive to a poorly differentiated invasive ductal carcinoma of the breast. The mastectomy specimen contained a lobulated mass, microscopically showing a partly epithelioid spindle cell tumor, immunoreactive for vimentin, desmin, smooth muscle actin antibodies, and negative for epithelial markers, hormone and growth factor receptors. Axillary lymph nodes were free of tumor. A primary leiomyosarcoma of the breast was diagnosed.
Collapse
Affiliation(s)
- E Székely
- Semmelweis University, 2nd Department of Pathology Ullôi út 93, Budapest, H-1091, Hungary.
| | | | | | | | | |
Collapse
|